Hormonal IUD (Mirena/Kyleena) vs Nurtec ODT: Side-Effect Profile Head-to-Head

Why Are These Two Drugs Being Compared?

These two medications sit in completely different therapeutic categories. One is a locally acting progestin-releasing intrauterine device; the other is an oral calcitonin gene-related peptide (CGRP) receptor antagonist. They are compared here because women, particularly in perimenopause, sometimes face overlapping symptom burdens, including heavy periods, hormonal fluctuations, and worsening migraine, and clinicians may discuss both in the same appointment.

No direct head-to-head randomized trial comparing the hormonal IUD to rimegepant exists. The evidence below is synthesized from their individual trial programs. Where data in women specifically is limited, this article says so.

What Is the Hormonal IUD (Mirena and Kyleena)?

The hormonal IUD releases levonorgestrel (LNG) locally into the uterine cavity. Mirena releases approximately 20 micrograms per day initially, declining to around 10 micrograms per day over five years. Kyleena releases approximately 17.5 micrograms per day, declining to 7.4 micrograms per day over five years, making it a lower-dose option often chosen by women who want to preserve more regular cycling.

How It Works in the Body

Levonorgestrel acts primarily on the endometrium, thickening cervical mucus and suppressing endometrial proliferation. Systemic absorption is low but measurable. Serum LNG levels with Mirena average roughly 150-200 picograms per milliliter, compared to several hundred picograms per milliliter seen with oral progestin pills, which is why systemic progestogenic side effects are less pronounced with the IUD than with oral progestins.

Who Uses It and Why

Women across several life stages choose the hormonal IUD for different reasons.

• Reproductive years: Highly effective reversible contraception (failure rate <1% per year) and management of heavy menstrual bleeding.
• Endometriosis and adenomyosis: Suppresses endometrial tissue and reduces dysmenorrhea, though it does not treat deep infiltrating endometriosis definitively.
• Perimenopause: Acts as the progestogen component of combined hormone replacement therapy (HRT) when an estrogen patch or gel is added, protecting the endometrium without a daily pill.
• Post-menopause (within licensed duration): Mirena is licensed in several countries as the progestogen arm of HRT for up to five years, though practitioners should confirm current local guidance.

The NEJM 2013 LNG-IUS trial for heavy menstrual bleeding found that the levonorgestrel IUS produced significantly greater reductions in menstrual blood loss and better quality-of-life scores than usual medical care including norethisterone, mefenamic acid, and combined oral contraceptives.

What Is Nurtec ODT (Rimegepant)?

Rimegepant is a small-molecule CGRP receptor antagonist approved by the FDA in February 2020 for acute treatment of migraine and in May 2021 for preventive treatment of episodic migraine in adults. The standard dose is 75 mg taken as an orally disintegrating tablet. For prevention, it is taken every other day.

How It Works in the Body

CGRP is a neuropeptide released during migraine attacks that dilates cranial blood vessels and amplifies pain signaling. Rimegepant blocks the CGRP receptor without causing vasoconstriction, which means it lacks the cardiovascular cautions associated with triptans. This distinction matters for women with cardiovascular risk factors, Raynaud phenomenon, or hemiplegic migraine, where triptans are avoided.

Rimegepant is metabolized primarily by CYP3A4 and to a lesser extent by CYP2C9. Women who take strong CYP3A4 inhibitors (such as ketoconazole or clarithromycin) should be aware that rimegepant exposure increases significantly, and the FDA prescribing information advises avoiding concomitant use.

Migraine Is a Women's Disease

Migraine affects approximately three times as many women as men after puberty, and hormonal fluctuations across the menstrual cycle, perimenopause, and the postpartum period are recognized triggers. Menstrual migraine, occurring in the window from two days before to three days after menstruation begins, is driven by the estrogen withdrawal that accompanies the late luteal phase. This is directly relevant to the choice of rimegepant: women with menstrual migraine may use it acutely during that window or as short-cycle prevention.

Side-Effect Profiles: A Detailed Comparison

The table below organizes known side effects by body system. Data comes from the Mirena and Kyleena prescribing information, the NEJM 2013 LNG-IUS trial, the Lancet 2021 rimegepant prevention trial, and the FDA-approved prescribing information for Nurtec ODT. Because no head-to-head trial exists, effect sizes are not directly comparable.

| Body System | Hormonal IUD (Mirena/Kyleena) | Nurtec ODT (Rimegepant) | |---|---|---| | Menstrual/uterine | Irregular spotting months 1-6; amenorrhea in up to 20% with Mirena at 1 year | No direct effect | | Gastrointestinal | Nausea (insertion period); mild cramping | Nausea (~2%), abdominal pain (~2%) | | Neurological/mood | Mood changes, headache reported in post-marketing; low systemic LNG limits CNS exposure | Nausea, rarely dizziness; no significant CNS depression | | Skin | Acne, hair thinning possible (androgenic activity of LNG) | Not reported | | Pelvic/local | Insertion pain, cramping, rare expulsion (~5%), rare uterine perforation (<1 in 1,000 insertions) | Not applicable | | Ovarian | Ovarian cysts (usually resolve spontaneously) in ~12% of Kyleena users | Not applicable | | Cardiovascular | Systemic LNG low; no established VTE risk from IUD-only LNG | No vasoconstriction; safer than triptans for cardiovascular risk | | Allergic | Rare nickel sensitivity (IUD frame) | Hypersensitivity reactions reported; dyspnea in <1% |

Menstrual and Hormonal Side Effects (IUD)

The most common reason women discontinue the hormonal IUD in the first year is unpredictable bleeding. In the NEJM 2013 trial, bleeding and spotting days at six months were higher in the LNG-IUS group than in the usual-care group before the significant reduction in heavy bleeding became apparent by twelve months. Women need to know that the first three to six months involve an adjustment phase, not a treatment failure.

Amenorrhea, complete absence of periods, occurs in roughly 20% of Mirena users by one year and fewer Kyleena users because of its lower hormone dose. For many women this is welcome. For others, especially those in perimenopause who want period confirmation that they have not yet reached menopause, it can cause anxiety.

Mood and Psychological Effects (IUD)

This is an area of genuine clinical debate and an evidence gap that deserves honest acknowledgment. Several observational studies, including a large Danish cohort of over one million women, have reported associations between hormonal contraceptive use and subsequent antidepressant prescriptions. The IUD showed a weaker association than combined oral contraceptives or hormonal patches, likely because systemic LNG levels are lower. However, the observational design of these studies does not establish causation, and many women report no mood changes at all.

If you have a personal or family history of depression, discuss this specifically with your prescriber before insertion. Mood changes that appear within the first three months of insertion and resolve after removal strongly suggest a causal link.

Side Effects of Rimegepant

The Lancet 2021 rimegepant prevention trial showed that patients receiving 75 mg every other day experienced a mean reduction of 4.3 fewer monthly migraine days compared to 3.5 in the placebo group, with a side-effect profile that was generally similar to placebo. Nausea was the most commonly reported adverse event, occurring in approximately 2% of rimegepant users versus 1.3% of placebo users, a small absolute difference.

Rimegepant does not cause the medication-overuse headache pattern seen with triptans and NSAID analgesics when used as an acute treatment, which is a clinically meaningful advantage for women who find themselves reaching for migraine relief more than ten days per month.

Life-Stage Guide: Which Side Effects Matter at What Age

Reproductive Years (Ages 18-40)

For contraception, the hormonal IUD offers set-it-and-forget-it reliability with primarily local side effects. The acne and hair-thinning risk with LNG is real but lower than with oral progestins because serum levels are lower. Women with a history of hormonal acne may prefer Kyleena over Mirena for its lower systemic dose, though no head-to-head acne comparison trial exists for the two devices.

Rimegepant is relevant in this group for menstrual migraine. The estrogen-withdrawal trigger in the late luteal phase is not addressed by the IUD; rimegepant can be taken acutely or preventively during the perimenstrual window.

Trying to Conceive

The IUD must be removed before attempting conception. Fertility returns rapidly after removal, typically within one to three cycles. Rimegepant is not recommended in women who are actively trying to conceive because adequate human pregnancy safety data are absent.

Perimenopause (Approximate Ages 45-55)

This is where the two medications are most likely to appear together in a single care plan. Perimenopause often brings both worsening migraine (due to erratic estrogen fluctuations) and heavier, more irregular periods. A Mirena IUD may be inserted to manage heavy perimenopausal bleeding, provide endometrial protection if systemic estrogen is added for menopausal symptoms, and reduce dysmenorrhea. At the same appointment, a clinician might prescribe rimegepant for the worsening migraine burden.

The Menopause Society (formerly NAMS) position statement on hormone therapy notes that the LNG-IUS is an appropriate progestogen delivery method for endometrial protection during perimenopausal and postmenopausal HRT.

In this population, the IUD side-effect profile shifts: irregular bleeding is still common initially, but the anti-proliferative effect on the endometrium is protective, and amenorrhea is often welcomed. Mood effects require attention because perimenopause itself carries elevated depression risk.

Post-Menopause

The hormonal IUD is used post-menopausally only in the context of HRT, as the progestogen component protecting the endometrium in women using systemic estrogen. Mirena is licensed for this use for up to five years in multiple countries.

Migraine frequency often declines after menopause when estrogen stabilizes at a consistently low level, though surgical menopause (bilateral oophorectomy) can worsen migraine. Rimegepant remains appropriate for post-menopausal women with ongoing episodic migraine.

Pregnancy, Lactation, and Contraception

Hormonal IUD

Pregnancy: The levonorgestrel IUD is one of the most effective contraceptives available, with a failure rate of approximately 0.1-0.2% per year. If pregnancy occurs with the IUD in place, there is a significantly elevated risk of ectopic pregnancy. The device should be removed as soon as an intrauterine pregnancy is confirmed; removal itself carries a risk of pregnancy loss. The FDA prescribing information for Mirena classifies it as contraindicated in known or suspected pregnancy.

Lactation: Levonorgestrel IUDs are considered compatible with breastfeeding by the CDC Medical Eligibility Criteria for Contraceptive Use. The device can be inserted four weeks or more postpartum. Systemic LNG transfer into breast milk is low, and no adverse effects on infant growth or development have been demonstrated in studies up to five years of follow-up.

Contraception note: Because the IUD is itself a contraceptive, no additional contraception is required for its primary user.

Rimegepant (Nurtec ODT)

Pregnancy: Rimegepant is not recommended during pregnancy. Animal studies at exposures higher than clinical doses showed adverse developmental effects. Human data are absent. The FDA prescribing information for Nurtec ODT states that women of reproductive potential should use effective contraception during preventive treatment and for at least five days after the last dose if stopping.

Lactation: It is unknown whether rimegepant or its metabolites are present in human milk. Because of potential risk to a nursing infant, the FDA prescribing information advises women to avoid breastfeeding during treatment and for five days after the last dose. This is particularly relevant for women in the postpartum period who have a history of migraine that worsens in the months after delivery.

Contraception requirement: Any woman of reproductive age using rimegepant for preventive treatment (every-other-day dosing) should use reliable contraception throughout the course of treatment and for five days after stopping.

Who This Is Right For and Who Should Be Cautious

Hormonal IUD: Well-Matched For

• Women wanting long-acting reversible contraception with minimal daily burden
• Women with heavy menstrual bleeding or dysmenorrhea from endometriosis or adenomyosis
• Perimenopausal women on systemic estrogen HRT who need progestogen cover without daily pills
• Women who have found systemic hormonal contraceptives cause mood or weight changes and want lower systemic progestin exposure

Hormonal IUD: Use With Caution or Avoid If

• You have unexplained uterine cavity abnormality or fibroids that distort the cavity
• You have current pelvic inflammatory disease or are at high risk of STI without a stable partner
• You have a history of ectopic pregnancy (relative caution; discuss with your provider)
• You have known or suspected hormone-sensitive malignancy (including certain breast cancers; discuss with oncology)

Rimegepant: Well-Matched For

• Women with episodic migraine who have cardiovascular risk factors, Raynaud phenomenon, or hemiplegic migraine that exclude triptan use
• Women who experience medication-overuse headache on triptans or NSAIDs
• Perimenopausal women with worsening menstrual or hormonal migraine
• Women who need both acute and preventive migraine coverage from a single agent

Rimegepant: Use With Caution or Avoid If

• You are pregnant or trying to conceive
• You are breastfeeding (five-day washout required)
• You take strong CYP3A4 inhibitors or strong P-glycoprotein inhibitors, which raise rimegepant exposure substantially
• You have severe hepatic impairment (avoid) or severe renal impairment (use with caution)

Interaction Risks Women Should Know

The hormonal IUD has very few drug-drug interactions because its action is primarily local. Certain enzyme-inducing drugs (rifampicin, carbamazepine, phenytoin) may theoretically reduce systemic LNG levels, but the local endometrial effect is generally considered sufficient for contraception; the evidence on this is not definitive, and some guidelines advise using additional contraception if taking these drugs.

Rimegepant has more interaction risk. Strong CYP3A4 inhibitors increase rimegepant area under the curve by more than fourfold; strong CYP3A4 inducers reduce exposure substantially, potentially reducing efficacy. Women taking antifungals, certain HIV protease inhibitors, or St. John's Wort should discuss this with their prescriber before starting rimegepant.

What the Evidence Gaps Mean for You

Women were historically underrepresented in migraine prevention trials, and CGRP antagonists including rimegepant have only recently been studied with any sex-stratified analysis. The Lancet 2021 prevention trial did not publish sex-stratified subgroup data in its primary report. The hormonal IUD literature is more female-specific by necessity, though women with PCOS, endometriosis, adenomyosis, and perimenopausal symptoms are often excluded from the primary contraception efficacy trials that form the evidence base.

This means that much of the practical guidance for using rimegepant in the context of menstrual migraine, or for using the hormonal IUD as an HRT component in perimenopausal migraine sufferers, is extrapolated from mechanistic understanding and clinical experience rather than directly studied in randomized controlled trials. Ask your clinician what specific evidence applies to your situation.

Practical Considerations: Cost, Access, and Follow-Up

The hormonal IUD requires an in-office procedure for insertion, typically covered by most insurance plans in the United States under the Affordable Care Act's contraceptive mandate. Out-of-pocket costs for Mirena can reach $1,300 without insurance. Once inserted, there is no daily cost or daily adherence burden.

Rimegepant is available by prescription and is covered by many commercial insurance plans, though prior authorization is common for the preventive indication. The wholesale cost per tablet is high (approximately $900 per month for every-other-day prevention dosing without coverage). Manufacturer copay assistance programs are available for commercially insured patients.

Follow-up for the IUD typically involves a string check at four to six weeks after insertion, then annual gynecologic visits. Rimegepant follow-up is at prescriber discretion, though a reassessment at three months is reasonable to evaluate migraine day reduction.